IP Library Granted Patent US 7,947,227
Granted Patent B2
US 7,947,227 · App. 12/076,723 · Granted May 24, 2011

Kit for the conversion of nitrogen dioxide (NO

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,947,227
App. No.
12/076,723
Granted
May 24, 2011
Kind
B2
Abstract

A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal.

Claims (49)

1. A kit for generating a therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal comprising:

a diffusion cell configured to be connected to a source of nitrogen dioxide;

a permeation tube connected to the diffusion cell; and

a receptacle configured to attach to the permeation tube, the receptacle including an inlet, an outlet, and a surface-active material coated with an antioxidant, wherein the inlet is configured to receive the flow of nitrogen dioxide from the permeation tube and fluidly communicate the flow to the outlet through the surface-active material to convert the gaseous nitrogen dioxide to nitric oxide at ambient temperature.

2. The kit of claim 1 , wherein the source of nitrogen dioxide is liquid nitrogen dioxide.

3. The kit of claim 1 , wherein diffusion cell is configured to provide the nitrogen dioxide at a diffusion rate of 200,000 ng per minute.

4. The kit of claim 1 , wherein the diffusion cell is made of stainless steel or plastic.

5. The kit of claim 1 , wherein the permeation tube length is scaled to provide a predetermined dose of nitrogen dioxide at a particular temperature.

6. The kit of claim 5 , wherein the permeation tube further comprises a movable, non-permeable sheath over the length of the tube.

7. The kit of claim 6 , wherein the sheath is configured to be removed prior to use.

8. The kit of claim 1 , wherein the permeation tube is connected to the diffusion cell through a diffusion needle.

9. The kit of claim 8 , wherein the diffusion needle is a narrow bore diffusion needle.

10. The kit of claim 8 , wherein the diffusion needle further comprises holes on the side of needle and an outer sheath surrounding the holes, wherein the sheath has slots fitted around the needle configured to be turned to uncover the uncover the desired hole.

11. The kit of claim 10 , wherein the holes on the side of the needle are at ¼, ½ or ¾ mark.

12. The kit of claim 8 , wherein the diffusion cell is connected to multiple permeation tube through multiple narrow bore diffusion needles.

13. The kit of claim 1 , wherein the receptacle comprises a cartridge.

14. The kit of claim 1 , wherein the surface-active material is saturated with the antioxidant.

15. The kit of claim 1 , wherein the surface-active material comprises a substrate that retains water.

16. The kit of claim 1 , wherein the surface-active material comprises a silica gel.

17. The kit of claim 1 , wherein the antioxidant comprises ascorbic acid.

18. The kit of claim 1 , wherein the antioxidant comprises alpha tocopherol or gamma tocopherol.

19. The kit of claim 1 , wherein the receptacle is a first receptacle, the kit further comprising a second receptacle including a second inlet, a second outlet, and a second surface-active material coated with an aqueous solution of an antioxidant, wherein the second inlet is configured to receive the flow from the first receptacle and fluidly communicate the flow to the second outlet through the second surface-active material to convert the gaseous nitrogen dioxide to nitric oxide at ambient temperature.

20. A kit for generating a therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal comprising:

a pressure regulator configured to be connected to a source of nitrogen dioxide;

a receptacle configured to attach to the pressure regulator, the receptacle including an inlet, an outlet, and a surface-active material coated with an aqueous solution of an antioxidant, wherein the inlet is configured to receive the flow from a source of gaseous nitrogen dioxide and fluidly communicate the flow to the outlet through the surface-active material to convert the gaseous nitrogen dioxide to nitric oxide at ambient temperature,

wherein the receptacle is configured to attach to the gas bottle having nitrogen dioxide in air and capable of providing a flow of gaseous nitrogen dioxide and air.

21. The kit of claim 20 , further comprising a gas bottle having nitrogen dioxide and capable of providing diffusing gaseous nitrogen dioxide into an air flow.

22. The kit of claim 20 , wherein the receptacle is placed on the low pressure side of the pressure regulator.

23. The kit of claim 20 , wherein the receptacle is a first receptacle, the kit further comprising a second receptacle including a second inlet, a second outlet, and a second surface-active material coated with an aqueous solution of an antioxidant, wherein the second inlet is configured to receive the flow from the first receptacle and fluidly communicate the flow to the second outlet through the second surface-active material to convert the gaseous nitrogen dioxide to nitric oxide at ambient temperature.

24. The kit of claim 20 , wherein the pressure regulator includes an inlet port and an outlet port that connects the receptacle with a gas bottle having nitrogen dioxide in air.

25. The kit of claim 20 , wherein the receptacle comprises a cartridge.

26. The kit of claim 20 , wherein the surface-active material is saturated with the aqueous solution of the antioxidant.

27. The kit of claim 20 wherein the surface-active material comprises a substrate that retains water.

28. The kit of claim 20 , wherein the surface-active material comprises a silica gel.

29. The kit of claim 20 , wherein the antioxidant comprises ascorbic acid.

30. The kit of claim 20 , wherein the antioxidant comprises alpha tocopherol or gamma tocopherol.

31. A method of providing a therapeutic amount of nitric oxide to a mammal comprising:

diffusing nitrogen dioxide into a gas flow;

exposing the nitrogen dioxide to a surface-active material coated with an antioxidant to convert the gaseous nitrogen dioxide to nitric oxide at ambient temperature; and

transporting the nitric oxide in a therapeutic amount to a mammal.

32. The method of claim 31 , wherein the nitrogen dioxide is generated from liquid nitrogen dioxide.

33. The method of claim 31 , wherein diffusing nitrogen dioxide into a gas flow includes providing the nitrogen dioxide at a diffusion rate of 200,000 ng per minute.

34. The method of claim 31 , wherein diffusing nitrogen dioxide into a gas flow includes providing a predetermined dose of nitrogen dioxide at a particular temperature.

35. The method of claim 31 , wherein the surface-active material is saturated with the antioxidant.

36. The method of claim 31 , wherein the surface-active material comprises a substrate that retains water.

37. The method of claim 31 , wherein the surface-active material comprises a silica gel.

38. The method of claim 31 , wherein the antioxidant comprises ascorbic acid.

39. The method of claim 31 , wherein the antioxidant comprises alpha tocopherol or gamma tocopherol.

40. The method of claim 31 , further comprising contacting the nitric oxide a second surface-active material coated with an antioxidant immediately prior to inhalation by the mammal.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2026
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: VERO BIOTECH INC.
Reel/Frame 075308/0198 →
SECURITY INTEREST Recorded Mar 16, 2026
From: VERO BIOTECH INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS COLLATERAL AGENT
Reel/Frame 075117/0935 →
SECURITY INTEREST Recorded Jan 3, 2024
From: VERO BIOTECH INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 066187/0865 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 3, 2024
From: RUNWAY GROWTH FINANCE CORP (F/K/A RUNWAY GROWTH CREDIT FUND INC.)
To: VERO BIOTECH INC. (F/K/A VERO BIOTECH LLC)
Reel/Frame 066186/0611 →
CHANGE OF NAME Recorded Feb 14, 2022
From: VERO BIOTECH LLC
To: VERO BIOTECH INC.
Reel/Frame 059085/0418 →
SECURITY INTEREST Recorded Dec 29, 2020
From: VERO BIOTECH LLC
To: RUNWAY GROWTH CREDIT FUND INC.
Reel/Frame 054866/0589 →
CHANGE OF NAME Recorded Jun 6, 2018
From: GENO LLC
To: VERO BIOTECH LLC
Reel/Frame 046304/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2008
From: FINE, DAVID H.; ROUNBEHLER, DAVID R.; VASQUEZ, GREG
To: GENO LLC
Reel/Frame 021379/0818 →